Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced the Risk of Disease Progression or Death by 83 Percent Compared to a Standard of Care Regimen in Previously Treated Chronic Lymphocytic Leukemia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the first results from the pivotal Phase III MURANO study evaluating Venclexta™ (venetoclax) plus Rituxan® (rituximab) compared to bendamustine plus Rituxan (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukemia (CLL). The results showed that a fixed duration of treatment with Venclexta plus Rituxan significantly reduced the risk o